Effect of spironolactone on ventricular arrhythmias in congestive heart failure secondary to idiopathic dilated or to ischemic cardiomyopathy
- PMID: 10802002
- DOI: 10.1016/s0002-9149(00)00729-3
Effect of spironolactone on ventricular arrhythmias in congestive heart failure secondary to idiopathic dilated or to ischemic cardiomyopathy
Abstract
Epidemiologic studies have shown an important increase in the high mortality of patients with congestive heart failure (CHF) despite optimal medical management. Ventricular arrhythmia was recognized as the most common cause of death in this population. Electrolyte imbalance, myocardial fibrosis, left ventricular dysfunction, and inappropriate neurohumoral activation are presumed responsible for sudden cardiac death. In this study, we focused on the deleterious effects of the overproduction of aldosterone that occurs in patients with CHF. Secondary hyperaldersteronism can be part of several factors thought to be responsible for sudden cardiac death. We randomized 35 patients (32 men, aged 48 +/- 9 years) with systolic dysfunction (ejection fraction 33 +/- 5%) and New York Heart Association class III CHF secondary to dilated or ischemic cardiomyopathy into 2 groups. The treatment group received spironolactone, an aldosterone receptor antagonist, along with standard medical management using furosemide, angiotensin-converting enzyme inhibitors, and digoxin. The control group received only the standard medical treatment. Holter monitoring was used to assess the severity of ventricular arrhythmia. After 20 weeks, patients who received spironolactone had a reduced hourly frequency of ventricular premature complexes (VPCs) (65 +/- 18 VPCs/hour at week 0 and 17 +/- 9 VPCs/hour at week 16) and episodes of nonsustained ventricular tachycardia (VT) (3.0 +/- 0.8 episodes of VT/24-hour period at week 0, and 0.6 +/- 0.3 VT/24-hour period at week 16). During monitored treadmill exercise, a significant improvement in ventricular arrhythmia was found in the group receiving spironolactone (39 +/- 10 VPCs at week 0, and 6 +/- 2 VPCs at week 16). These findings suggest that aldosterone may contribute to the incidence of ventricular arrhythmia in patients with CHF, and spironolactone helps reduce this complication.
Similar articles
-
[Effect of long term therapy with spironolactone on parameters of 24-hour heart rhythm variability and ventricular arrhythmias in patients with heart failure receiving optimal therapy].Kardiologiia. 2008;48(2):52-64. Kardiologiia. 2008. PMID: 18261010 Clinical Trial. Russian.
-
Significance of ventricular arrhythmias in idiopathic dilated cardiomyopathy.Am J Cardiol. 1984 Mar 15;53(7):902-7. doi: 10.1016/0002-9149(84)90522-8. Am J Cardiol. 1984. PMID: 6702645
-
Efficacy and safety of berberine for congestive heart failure secondary to ischemic or idiopathic dilated cardiomyopathy.Am J Cardiol. 2003 Jul 15;92(2):173-6. doi: 10.1016/s0002-9149(03)00533-2. Am J Cardiol. 2003. PMID: 12860219 Clinical Trial.
-
Treatment of congestive heart failure: interfering the aldosterone-cardiac extracellular matrix relationship.Hypertension. 2001 Nov;38(5):1227-32. doi: 10.1161/hy1101.099484. Hypertension. 2001. PMID: 11711528 Review.
-
Spironolactone in congestive heart failure.Curr Hypertens Rep. 2000 Oct;2(5):451-6. doi: 10.1007/s11906-000-0027-x. Curr Hypertens Rep. 2000. PMID: 10995520 Review.
Cited by
-
Update on Renin-Angiotensin-aldosterone blockade in heart failure.Curr Treat Options Cardiovasc Med. 2009 Dec;11(6):455-66. doi: 10.1007/s11936-009-0048-y. Curr Treat Options Cardiovasc Med. 2009. PMID: 19930983
-
A propensity-matched study of low serum potassium and mortality in older adults with chronic heart failure.Int J Cardiol. 2009 Sep 11;137(1):1-8. doi: 10.1016/j.ijcard.2008.05.047. Epub 2008 Aug 8. Int J Cardiol. 2009. PMID: 18691778 Free PMC article. Clinical Trial.
-
[Guidelines for therapy of chronic heart failure].Z Kardiol. 2005 Aug;94(8):488-509. doi: 10.1007/s00392-005-0268-4. Z Kardiol. 2005. PMID: 16049651 German. No abstract available.
-
Third-generation Mineralocorticoid Receptor Antagonists: Why Do We Need a Fourth?J Cardiovasc Pharmacol. 2016 Jan;67(1):26-38. doi: 10.1097/FJC.0000000000000329. J Cardiovasc Pharmacol. 2016. PMID: 26466326 Free PMC article. Review.
-
Rationale for the use of aldosterone antagonists in congestive heart failure.Drugs. 2002;62(5):723-31. doi: 10.2165/00003495-200262050-00001. Drugs. 2002. PMID: 11929327 Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical